←ISRGIntuitive SurgicalOur view: UnattractiveFull analysisעברית
Updated 16 Nov 2026
The company · 1 · Who is this company?

Intuitive makes the da Vinci surgical robot

da Vinci

robot arms for surgery

Wristed instruments

bend at the tip

3.15 million

operations on it in 2025

The da Vinci replaces keyhole and open surgery with instruments that bend at the tip, which a surgeon drives from a console.

The company · 2 · What exactly does it sell?

Instruments used per operation lead

Each $1 of sales, 2025
60%25%16%
Instruments per operationRobotsService

Hospitals buy the robot once and buy instruments for every operation.

The company · 3 · How does it make money?

The robot once, instruments every operation

About $1,830of instruments per operation
+14%operations worldwide
3% to 5%price cut from 2027

Each robot installed brings years of instrument and service sales.

Is it a good business? · 4 · What gives it an edge?

Once bought, the robot locks in its instruments

76.3%

of revenue from instruments and service, June quarter

2024

a court found monopoly power, then withdrew it

Each instrument stops after a set number of uses, and leaving means writing off the machine and retraining the team.

Is it a good business? · 5 · What is the catch?

Rivals attack from three sides

MedtronicHugo robot cleared for urology
J&Jfiled its Ottava robot
Restore Roboticsrebuilds Intuitive's own instruments

Listed rivals: MDT · JNJ

Rebuilt instruments go straight after the recurring revenue the robot earns.

Is it a good business? · 6 · What does its record show?

Revenue doubled with profit steady

Sales, $B
5.7
6.2
7.1
8.4
10.1
11.6
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales$5.71B → $11.6Brevenue, 2021 to the past year
Profit32% → 28%operating profit per $1
Kept69% → 67%kept per $1 after making it

Lower selling costs were offset by research and a thinner share kept per sale, on mix and tariffs.

Is it a good business? · 7 · How much room is there to grow?

The count misses much of the market

About $3.92Ba year from US inpatient robotic operations
$4.72Bits US instrument sales already
15.1%robotic share last measured, Michigan

Outpatient operations and new uses push the real market well beyond that count.

Is it a good business? · 8 · Who is in charge?

An engineer with 30 years there took over

July 2025Dave Rosa became chief executive
2022Jamie Samath took over finance
Gary Guthartthe former chief, now full-time chair

Guthart, who ran it before, stays on as full-time chair.

The story right now · 9 · Why do hospitals use surgical robots?

Robots make keyhole surgery easier

3.15 millionda Vinci operations, 2025
+14%operation growth
+10%US growth, slowest in years

Robots let surgeons do through small cuts what once needed open surgery, so patients recover faster. Growth abroad is fast; the US is maturing.

The story right now · 10 · Can volume make up the price cut?

More operations must offset cheaper instruments

  1. Instrument prices cut3% to 5% from 2027.
  2. Revenue per operation fallsBy that much.
  3. Needs 3.1% to 5.3% moreOperations to offset.
  4. US growth slowedTo 10%.

The cut is smaller than the 7% of the 2020 programme, but the reason for it sits in a court docket and the regulator's clearances.

The story right now · 11 · What changed lately?

Revenue up 22%, the price cut sized

$3.00adjusted profit per share, beat
+14%da Vinci operations
+10%US operations, slowing
$450Mto settle the hospital class action

Mixed quarter

American operations grew only 10%, below our line, so the test read against us.

The story right now · 12 · What is everyone arguing about?

Insurance losses, or its own price cut?

Many investors think

Lost health insurance will slow paid operations

We think

Its own price cut and slower US growth matter more

We would be wrong if US operations speed back up and more operations outrun the cut.

The price and our view · 13 · What is a share worth?

The price sits far above our value

$213what we think a share is worth
$213our value
Attractive
below $170
Neutral
Unattractive
above $256
$119gloomy: growth halves, less kept per $1
$213our estimate: experts' path, then slowing
$279sunny: growth beats the forecast by a quarter

Value per share in three futures. None is a prediction of the share price.

We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.

The price and our view · 14 · How could we be wrong?

A deeper price cut is the biggest risk

A deeper cutBiggest

Above 5% of revenue.

Slower US growthShowing now

Down to 10%.

Rebuilt instrumentsWatch

Cleared and selling.

What the cut isUnknown

China's share unsplit.

Rival robots and the courts could each push prices lower again.

The price and our view · 15 · How will we know?

January brings the 2027 forecast

US operations speed back upGood sign
Price cut held at 3% to 5%Good sign
Rebuilt instruments spreadBad sign
JAN 202728

Fourth-quarter 2026 results and the 2027 forecast, 28 January. Companies report every three months; each report is a test of the story.

Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.

The price and our view · 16 · So, what do we think?

An excellent business, priced as though little changes

$213our value
Attractive
below $170
Neutral
Unattractive
above $256

UnattractiveHigh conviction

Intuitive makes the da Vinci surgical robot, and hospitals buy its instruments for every operation. But it will cut instrument prices from 2027, US operations grew only 10% last quarter and rebuilt instruments compete.

↑ ↓ to move · C for contents